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Abstract
Background: Paraneoplastic syndromes are most frequently associated with small cell lung carcinoma, hematologic
and gynecologic malignancies while reports in head and neck cancer are rare.
Case presentation: We present the case of a 60-year old female patient who developed paraneoplastic cerebellar
degeneration upon locoregional recurrence of a poorly differentiated spindle cell carcinoma of the nasal cavity and
paranasal sinus. The neurological symptoms, especially ataxia, stabilized after resection of tumor recurrence and
concomitant chemoradiotherapy whereas anti-Hu-antibodies remained positive. Despite the unfavorable prognosis
of paraneoplastic neurological disorders associated with onconeural antibodies, the patient achieved long-standing
stabilization of neurological symptoms.
Conclusion: We report the first patient with anti-Hu antibodies and paraneoplastic cerebellar degeneration associated
with a spindle cell carcinoma of the head and neck. We recommend that evaluation of neurological symptoms in
patients with this tumor entity should also include paraneoplastic syndromes as differential diagnoses and suggest
early extensive screening for onconeural antibodies.
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Background
Paraneoplastic syndromes are described as a heteroge-
neous group of disorders in the presence of a tumor with
symptoms that do not originate from growth of cancer,
metastatic spread, or infectious, toxic and metabolic
effects associated with the underlying malignancy [1].
Depending on the affected organ system, endocrine,
hematological, dermatological, rheumatological as well
as neurological paraneoplastic syndromes have been de-
scribed. For paraneoplastic syndromes, an association
with various types of cancer – including small cell lung
cancer (SCLC), thymoma, Hodgkin- and Non-Hodgkin-
lymphoma and gynecological malignancies – has been
demonstrated [2, 3].
Patients with primary cancer of head and neck rarely
present with paraneoplastic syndromes, most of them
are associated with squamous cell carcinomas [4, 5].
Among paraneoplastic neurological syndromes (PNS) in
patients with head and neck cancer, only a few cases
with paraneoplastic cerebellar degeneration (PCD) have
been described so far [6, 7]. PCD is characterized by ver-
tigo, nystagmus and rapidly progressing cerebellar ataxia
with a poor median survival [3].
Diagnostic criteria recommended by the PNS Euronet-
work help to distinguish “definite” from “possible” PNS
depending on the presence of classical or non-classical
neurological syndromes, presence of distinct onconeural
antibodies, presence of a tumor, and improvement of
symptoms after cancer therapy [8]. Treatment of cancer
* Correspondence: a.egle@salk.at
1Third Medical Department with Hematology, Medical Oncology,
Hemostaseology, Infectious Diseases and Rheumatology, Oncologic Center,
Salzburg Cancer Research Institute with Laboratory of Immunological and
Molecular Cancer Research and Center for Clinical Cancer and Immunology
Trials, Paracelsus Medical University Salzburg, Muellner Hauptstrasse 48, 5020
Salzburg, Austria
Full list of author information is available at the end of the article
© 2015 Huemer et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Huemer et al. BMC Cancer  (2015) 15:996 
DOI 10.1186/s12885-015-2020-4
is still the main therapy of paraneoplastic neurological
phenomena although development as well as persistence
of PNS in remission have been described [9].
We report the first patient with a spindle cell carcin-
oma of the nasal cavity and paranasal sinus presenting
PCD associated with anti-Hu antibodies and describe
the clinical presentation as well as diagnostic work-up.
Based on our findings, we suggest to screen neurologic-
ally symptomatic patients with head and neck tumors
for a paraneoplastic syndrome.
Case presentation
In November 2008, an otherwise healthy 60-year old
Caucasian female presented at the department of oto-
rhinolaryngology due to right-sided limited nasal breath-
ing accompanied by bloody nasal discharge. Aside from
tonsillectomy and partial dentures, her past medical
history, including alcohol and nicotine, was unremarkable.
Examination with nasal specula showed a tumor covered
with bloody secretions, completely occupying the right
nasal meatus in the absence of cervical lymphadenopathy
assessed by palpation. Magnetic resonance imaging (MRI)
revealed nasal septal deviation due to a 5 × 2.2 × 4.5 cm
measuring mass located in the right nasal meatus and right
ethmoid sinus, highly suspicious of malignant origin
(Fig. 1a). The tumor was removed by functional endoscopic
sinus surgery. Based on histological and immunohisto-
chemical results, showing epithelial as well as mesenchymal
differentiation (Fig. 2), and absence of molecular transloca-
tion t(X,18), the diagnosis of a spindle cell carcinoma,
formerly called carcinosarcoma, was made (cT3 N0 M0).
Following this diagnosis, 18F-fluorodeoxyglucose
positron emission tomography/computed tomography
(18F-FDG PET/CT) imaging showed a solitary 1 × 1.3 cm
residual lesion in the right nasal meatus which neces-
sitated surgical re-resection followed by adjuvant
radiotherapy without adjuvant chemotherapy, leading
to a cumulative radiation dose of 61.1 gray (Gy) in
the tumor bed.
At follow-up in December 2009, a solitary firm and
immobile mass beneath the left jaw angle was palpated on
physical examination. Two spherical 1.5 cm measuring
lymph nodes were detected by MRI (Fig. 1b) and intense
tracer uptake was demonstrated by 18F-FDG PET/CT
imaging.
Prior to the planned neck dissection, in January 2010,
the previously asymptomatic patient complained about
progressive gait instability accompanied by vertigo and
nausea. Detailed neurologic examination revealed central
nystagmus, bilateral dysdiadochokinesia, distal pallhy-
pesthesia affecting the lower extremities, bilateral dys-
metria on finger-nose-test, an ataxic gait and a positive
Romberg test. Although ischemia, hemorrhage, malig-
nancy as well as other morphological abnormalities of
the cerebellum and cerebrum were immediately ruled
out by CT and MRI of the head, the patient’s neuro-
logical symptoms deteriorated, necessitating the use of a
walking aid.
In February, left-sided level II neck dissection took
place and histologic work-up of the suspicious lymph
nodes confirmed locoregional recurrence of the previ-
ously described spindle cell carcinoma. A short-term
neurologic reevaluation confirmed persistence of cere-
bellar symptoms. In order to rule out infectious causes
and autoimmune processes, serologic testing for syphilis
and Lyme disease were done, but results were unremark-
able. In addition, two sequential lumbar punctures were
performed, cerebrospinal fluid analysis revealed cell
Fig. 1 Magnetic Resonance Imaging of the Primary Tumor and Lymph Node Metastases. November 2008, coronal MRI with contrast of the head
showing the primary tumor in the right main nasal meatus and ethmoid sinus (a). December 2009, coronal MRI with contrast of the head and neck
demonstrating two spherical, enlarged cervical lymph nodes on the contralateral side (b)
Huemer et al. BMC Cancer  (2015) 15:996 Page 2 of 6
counts (erythrocytes: 3/μl and 12/μl; monocytes: few;
lymphocytes: few) and serum chemistry (total protein:
48 mg/dl and 44 mg/dl; glucose: 56 mg/dl and 57 mg/dl;
lactate: 1.7 mmol/l and 1.8 mmol/l) within normal limits
in the absence of malignant cells. Polymerase chain reac-
tion and serology testing for commonly tested viruses
(Herpes simplex virus, Varicella zoster virus, Ebstein-
Barr virus, Cytomegaly virus, Tick-borne encephalitis
virus, Enterovirus), protozoa (Toxoplasma gondii) and
bacteria (Listeria, Borrelia) was negative. Magnetic res-
onance imaging of the spine was performed but did not
show any morphological abnormalities either. Subse-
quently, the patient’s serum was analyzed for onconeural
antibodies in order to investigate the possible role of a
paraneoplastic syndrome in this case. The presence of
anti-Hu antibodies was demonstrated by a tissue based
assay for intracellular antigens, using an avidin-biotin per-
oxidase technique on frozen sections of rat cerebellum
(antibody titer 1:2000; Fig. 3a/b) and confirmed by a
recombinant immunoblot (ravo Diagnostika GmbH,
Freiburg, Germany). Nerve conduction testing revealed
the presence of demyelinating as well as axonal polyneur-
opathy of the lower extremities, affecting motor and
sensory nerves. With regard to all findings, the patient’s
neurological presentation was classified as paraneoplastic
cerebellar degeneration. In the absence of other potential
causative neurotoxic factors in the patient’s history, the
polyneuropathy documented in parallel was also consid-
ered of paraneoplastic origin in association with detectable
anti-Hu antibodies in the patient’s serum.
Fig. 2 Histology and Immunohistochemistry of the Primary Tumor and Lymph Node Metastasis. Hematoxylin and Eosin (HE) stain of the primary
tumor (a) and metastasis (b) shows the biphasic morphology of the spindle cell carcinoma. Immunohistochemical staining with AE1/AE3 demonstrates
the epithelial elements of the primary tumor (c) and the cervical lymph node metastasis (d) whereas vimentin, a marker of epithelial-to-mesenchymal
transition, spares these parts (e, f)
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Adjuvant concomitant chemoradiotherapy of the left
neck with 64.6 Gy was initiated and the patient received
two cycles of platinum-based chemotherapy at 21-day
intervals starting in March 2010. In the light of the
patient’s documented neuropathy, carboplatin AUC (area
under the curve) 5 was preferred over cisplatin for
concomitant use with radiotherapy due to its lower
potential for peripheral neurotoxicity.
Complete remission was confirmed after multimodal
cancer treatment and structural cerebellar and cerebral
abnormalities were again ruled out by MRI of the head.
After several months, the patient’s neurological symp-
toms, especially ataxia, had reached a plateau and she
maintained her ambulatory ability by the use of a
wheeled walker. On a regular basis, close interdisciplin-
ary follow-up visits at the oncology and otorhinolaryn-
gology department took place. Our patient remained in
complete remission for the following 3 years without
deterioration of ataxic gait or vertigo. Follow-up study of
serum only revealed a slight decline of anti-Hu antibody
titer (1:500). Immunohistochemical analysis on formalin-
fixed and paraffin-embedded biopsy material of the pri-
mary tumor and the lymph node metastasis (not shown)
with biotinylated anti-Hu IgG (obtained from an anti-Hu
positive serum) showed strong nuclear expression of the
Hu-antigen in the majority of tumor cells (Fig. 3c, d).
However, in comparison to the primary tumor, the lymph
node metastasis contained a substantial fraction dediffer-
entiated cells characterized by enlarged nuclei and
enlarged cytoplasm.
As the patient’s neurological complaints remained
stable for more than 3 years after effective anticancer
therapy and considering the unsatisfying treatment re-
sponses described in the literature, we decided against
immunosuppressive therapy or plasmapheresis.
Discussion & conclusion
We present the first case of a patient with an underlying
spindle cell carcinoma, formerly called carcinosarcoma,
of the nasal cavity and ethmoid sinus who developed
PCD associated with anti-Hu antibodies [10]. The ma-
jority of patients with PCD present with gynecological
and breast cancer (anti-Yo or anti-Ri) as well as with
SCLC (anti-Hu) [3]. In contrast, PNS are rarely observed
in patients with head and neck cancer. Only two cases
of PCD are reported, one laryngeal carcinoma without
Fig. 3 Immunohistochemistry on Rat Cerebellum and Primary Tumor Biopsy. Anti-Hu antibodies in the patient’s serum show an intensive labeling
of nuclei and cytoplasm of brain stem neurons (arrowheads) (a). Serum of a healthy individual remains negative (b). Biopsy of the primary tumor
reveals strong expression of Hu-antigen in the majority of tumor cells (c; biotinylated anti-Hu IgG). Staining with a biotinylated control IgG remains
negative (d). Magnification: x400
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onconeural antibodies and one squamous cell carcinoma
of the tongue with anti-CV2 antibodies [6, 7]. The spin-
dle cell carcinoma of our patient (primary tumor and
lymph node metastasis) showed strong immunoreactivity
of the Hu-antigen, which confirms the association of
anti-Hu antibodies and PCD associated with this type of
tumor. Although the Hu-antigen was already expressed
in the primary tumor, our patient’s neurological symp-
toms only started 1 year later at the time of tumor
recurrence. In the majority of cases the PNS precedes
the diagnosis of the underlying malignancy, however, it
is not unusual that the neurological symptoms occur
later during tumor recurrence and might be explained
by altered antigen-presentation in the course of tumor
dedifferentiation [3].
In most patients suffering from PCD, prognosis is
determined by the outcome of their neurological syn-
drome rather than by the underlying malignancy. A
retrospective analysis by Shams’ili et al. demonstrated
poor neurological outcome and overall survival of pa-
tients with PCD, especially for those with detectable
anti-Hu antibodies with a median survival of 7 months
[3]. Antitumor therapy is still the gold standard for treat-
ment of the neurological disorder while therapeutic
approaches with immunoglobulins, cytotoxic agents,
steroids or plasmapheresis aiming at stabilization or
improvement of neurological symptoms proved to be of
limited success [3, 11–13]. In contrast to the previously
described common course of disease, our patient’s
neurological symptoms stabilized after successful multi-
modal cancer therapy and she remained ambulatory with
a walking aid for more than 3 years after development of
PCD. It is noteworthy that the anti-Hu antibody titer in
the patient’s serum had not significantly changed despite
of complete remission for 3 years and stabilization of
neurological symptoms. We also point out that results of
nerve conduction testing were consistent with the
presence of a mixed polyneuropathy, which might have
contributed to the patient’s walking difficulties aside
from cerebellar ataxia. In this respect, an association
between non-cerebellar neurological manifestations and
anti-Hu antibodies in patients with PCD has been
observed [3]. Furthermore, in a retrospective analysis
Camdessanché et al. describe paraneoplastic peripheral
neuropathies in patients with positive anti-Hu antibodies
in the serum [14].
Our approach in case of onset of new neurological
symptoms associated with a known underlying malig-
nancy (e.g. in head & neck cancer) includes obtaining
detailed medical history, a thorough neurologic examin-
ation and neuroimaging (preferably MRI), and concomi-
tant onconeural antibody screening in the patients’ sera
[8]. Onconeural antibodies are most likely an epiphe-
nomenon and T-cells lead to destruction of neurons and
cell death. This is also reflected by the constant antibody-
titer in our patient, despite of clinical stabilization and
tumor remission. However, the antibodies serve as excel-
lent biomarker in the diagnosis of a PNS. Detection of anti-
neuronal antibodies is minimally invasive and helps to
distinguish between autoimmune nature and treatment re-
lated side effects as putative cause of neurological disease.
The diagnostic value of onconeural antibodies is character-
ized by a high specificity, whereas sensitivity is low to mod-
erate meaning that PNS can occur without antibodies and
a negative test result does not rule out presence of PNS
[15]. Absence or presence of onconeural antibodies does
not influence therapy of PNS, which is treatment of the
underlying malignancy, instead, detection of these anti-
bodies combined with consideration of the individual
neurological syndrome is of prognostic value as overall
survival is often limited by neurological outcome [3].
In summary, our case has several practical implica-
tions. First, in patients with head and neck tumors who
develop neurological symptoms, a PNS should be
considered as differential diagnosis. Second, despite of
usually limited survival of patients with PNS associated
with onconeural antibodies, long-lasting stabilization of
neurological symptoms can be achieved by effective
multimodal therapy of the underlying malignancy. Third,
extensive screening of onconeural antibodies is import-
ant in order to establish/confirm the diagnosis of PNS
and to evaluate prognosis.
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